Polyrizon (PLRZ) vs Quoin Pharmaceuticals (QNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Polyrizon (PLRZ) has outperformed Quoin Pharmaceuticals (QNRX) over the past year, gaining 23.2% versus a loss of 44.4%. Polyrizon is the larger company by market cap ($21.8 million vs $21.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLRZ | QNRX |
|---|---|---|
| Share price | $8.99 | $4.50 |
| Market cap | $21.83M | $21.62M |
| 1-day change | +1.33% | -1.10% |
| YTD return | +4.48% | -68.47% |
| 1-year return | +23.19% | -44.44% |
| 5-year return | — | -99.99% |
| EPS (TTM) | $-4.97 | $-5.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.20 | $41.80 |
| 52-week low | $2.88 | $3.25 |
| Distance from 52-week high | -50.61% | -89.23% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +385.11% |
| Average volume | 60.55K | 541.11K |
| Shares outstanding | 2.43M | 4.80M |
| Employees | 2 | 4 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLRZ has outperformed QNRX by 67.6 percentage points over the past year.
About Polyrizon
PLRZ stock →Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.
Health Care · Medical/Dental Instruments · 2 employees
About Quoin Pharmaceuticals
QNRX stock →Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
PLRZ vs QNRX FAQ
Which is bigger, Polyrizon or Quoin Pharmaceuticals?
Polyrizon (PLRZ) is larger, with a market capitalization of $21.83M compared with $21.62M for Quoin Pharmaceuticals (QNRX).
Which stock has performed better over the past year, PLRZ or QNRX?
PLRZ returned +23.19% over the past 12 months, compared with -44.44% for QNRX (price return, excluding dividends). Past performance does not predict future results.
Are Polyrizon and Quoin Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Polyrizon and Biotechnology: Pharmaceutical Preparations for Quoin Pharmaceuticals.